Galectin Therapeutics Inc. Reports H1 2026 Financial Results

What Happened
On August 14, 2026, Galectin Therapeutics, Inc. filed a Form 8‑K (Item 2.02) and issued a press release announcing its results of operations and financial condition as of and for the six months ended June 30, 2026, along with a business update. The press release is attached as Exhibit 99.1 and is incorporated by reference into the 8‑K. The company notes that statements in the release include forward‑looking statements subject to risks and uncertainties.

Key Details

• Filing and press release date: August 14, 2026. Reporting period: six months ended June 30, 2026.
• Press release summarizing H1 2026 results and business update is attached as Exhibit 99.1 to the 8‑K.
• Forward‑looking statements are included and covered by the Private Securities Litigation Reform Act safe harbor; investors are directed to the “Risk Factors” in Galectin’s Form 10‑K for the year ended December 31, 2025.

Why It Matters
This 8‑K signals that Galectin has released interim financial results (H1 2026) and operational updates that could affect assessments of its earnings, revenue trends, cash position and clinical or development progress. Retail investors should read the attached press release and recent SEC filings to see the specific financial figures and management commentary, and consider the disclosed risks when evaluating the company’s outlook.